Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenazopyridine for urinary flow and symptom relief in benign prostatic hyperplasia
IRCT20260710070115N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of phenazopyridine in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Urinary flow rate and International Prostate Symptom Score. Started Oct 2026; status: completed.
02
Drugs
phenazopyridine
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on IRCT20260710070115N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260710070115N1.